Dyne partnered with Duchenne muscular dystrophy (#DMD) and myotonic dystrophy type 1 (#DM1) advocates across the globe to inform the design of our clinical trials and to reduce the burdens and inconveniences to trial participants and their families. These findings were published in the journal Research Involvement and Engagement. In honor of #WDAD24 and International #MyotonicDystrophy Awareness Day this month, we're excited to share an insightful conversation from Pat Furlong, founding president and CEO of Parent Project Muscular Dystrophy (PPMD) and Ashish Dugar, PhD, MBA, our Chief Medical Affairs Officer, about this collaboration. Watch the full video: https://bit.ly/3N3brVP and read the paper: https://bit.ly/4dMU8mW #clinicialtrials #patientcenteredresearch
Congratulations! Great work. So happy to follow this!
Fantastic work with the patient community. Very exciting!
Great conversation!
SVP and Head of Clinical Development Operations
1moThis is great work and something we should all be striving towards!